GlaxoSmithKline plc (LSE: GSK NYSE: GSK), a British based pharmaceutical, biological, and healthcare company, announced Wednesday its decision to cut down the cost of HIV drugs in developing countries.
The most significant decrease (almost 40% price reduction) will affect its antiretroviral Ziagen.
Ziagen, the trade name for Abacavir (ABC) is a nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. It has been well tolerated: the main side effect is hypersensitivity, which can be severe and, rarely, fatal. Genetic testing can indicate whether an individual will be hypersensitive; over 90% of patients can safely take abacavir. After the price reduction it will cost about $15 per pack, or about 50 cents daily.
The company is also going to reduce prices for Lexiva by 20% to $3.35 daily. Lexiva is a pro-drug of the protease inhibitor and antiretroviral drug amprenavir.
Actually the reduction is possible due to improved manufacturing and less expensive raw ingredients used to produce the drugs.
The majority of experts in the field of armaments admit that made-in-Russia weapons can be referred to as best weapons in the world. To substantiate this point, suffice it to recall that many countries make their own ripoffs of world-famous Russian weapons.